ReviewStem cells international2016
iPSCs: A Minireview from Bench to Bed, including Organoids and the CRISPR System.
Review in Stem cells international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Combination of tumor organoids with advanced technologies: A powerful platform for tumor evolution and treatment response (Review).Molecular medicine reports · 2025Review
- Review
- Gene therapy for polygenic or complex diseases.Biomarker research · 2024Review
- COVID-19 and the role of stem cells.Regenerative therapy · 2021Review
- Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.Stem cells (Dayton, Ohio) · 2021Article
- Advances in removing mass transport limitations for more physiologically relevantBiophysics reviews · 2021Review
- Article
- Protein Kinases and Their Inhibitors in Pluripotent Stem Cell Fate Regulation.Stem cells international · 2019Review
- Induced Pluripotent Stem Cells to Study Mechanisms of Laminopathies: Focus on Epigenetics.Frontiers in cell and developmental biology · 2018Review
- 3D brain Organoids derived from pluripotent stem cells: promising experimental models for brain development and neurodegenerative disorders.Journal of biomedical science · 2017Review
- oRGs and mitotic somal translocation - a role in development and disease.Current opinion in neurobiology · 2017Review
- Induced pluripotent stem cell technology: a decade of progress.Nature reviews. Drug discovery · 2017Review
- From Reductionism to Holism: Toward a More Complete View of Development Through Genome Engineering.Advances in experimental medicine and biology · 2017Review
- CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.The Korean journal of internal medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When Dolly the sheep was born, the first probe into an adult mammalian genome traveling back in time and generating a whole new animal appeared. Ten years later, the reprogramming process became a defined method of producing induced pluripotent stem cells (iPSCs) through the overexpression of four transcription factors. iPSCs are capable of originating virtually all types of cells and tissues, including a whole new animal. The reprogramming strategies based on patient-derived cells should make the development of clinical applications of cell based therapy much more straightforward. Here, we analyze the current state, opportunities, and challenges of iPSCs from bench to bed, including organoids and the CRISPR system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.